©2019 by CBD Research Group. Proudly created with Wix.com

ANXIETY

Search and Discover

ANXIETY

1.) Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

https://www.ncbi.nlm.nih.gov/pubmed/30328956

“Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS (Visual Analogue Mood Scale) scores were observed between groups receiving CBD 150 mg, 600 mg and placebo.”

2.) Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007658/

“Promising areas of study that require further research include the use of MM in social anxiety disorder and schizophrenia: an important point being that the active medications in these studies were formulations of pure CBD.”

3.) A naturalistic examination of the perceived effects of cannabis on negative affect

https://www.sciencedirect.com/science/article/pii/S0165032718303100?via%3Dihub

“Medical cannabis users perceived a 50% reduction in depression and a 58% reduction in anxiety and stress following cannabis use. Two puffs were sufficient to reduce ratings of depression and anxiety, while 10+ puffs produced the greatest perceived reductions in stress. High CBD (>9.5%)/low THC (<5.5%) cannabis was associated with the largest changes in depression ratings, while high CBD (>11%)/high THC (>26.5%) cannabis produced the largest perceived changes in stress.”

4.) Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety‐related and substance abuse disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595771/

“Studies have begun to elucidate the neural circuit mechanisms underlying the effects of CBD on anxiety and learned fear. The recent functional imaging studies in humans, which examined the alterations in brain activity that accompany the anxiolytic effects of CBD, may inform future preclinical and clinical studies investigating the wider neural circuitry involved in mediating its effects on learned fear.”

5.) Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5121237/

“The opposing effects of CBD on fear memory reconsolidation and extinction make it particularly attractive as a potential adjunct to psychological therapy as both may lead to lasting reductions in learned fear expression. Our novel data also suggests that CBD reduces the expression of fear memory related to both discrete and contextual cues.”

6.) Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101100/

“A trial of cannabidiol oil resulted in a maintained decrease in anxiety and a steady improvement in the quality and quantity of the patient’s sleep.”

7.) Evidences for the Anti-panic Actions of Cannabidiol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412699/

“In the present review, we included both experimental laboratory animal and human studies that have investigated the putative anti-panic properties of CBD. Taken together, the studies assessed clearly suggest an anxiolytic-like effect of CBD in both animal models and healthy volunteers.”

8.) Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818147/

“A review of the findings suggests that CBD may attenuate motivational dysfunction through activation of the 5-HT1A receptor and elevations in eCB tone. Given the multitude of molecular targets for CBD, there is substantial potential for additional beneficial effects through actions at other receptors.”

9.) Cannabidiol as a Potential Treatment for Anxiety Disorders

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/

​“Preclinical evidence conclusively demonstrates CBD’s efficacy in reducing anxiety behaviors relevant to multiple disorders, including PTSD, GAD, PD, OCD, and SAD, with a notable lack of anxiogenic effects. CBD’s anxiolytic actions appear to depend upon CB1Rs and 5-HT1ARs in several brain regions; however, investigation of additional receptor actions may reveal further mechanisms. Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile.”

10.) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000500008&lng=en&nrm=iso&tlng=en

“Studies using animal models of anxiety and involving healthy volunteers clearly suggest an anxiolytic-like effect of CBD. Moreover, CBD was shown to reduce anxiety in patients with social anxiety disorder.”

11.) Cannabidiol in humans-the quest for therapeutic targets.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763649/

“Finally, preliminary clinical trials suggest that high-dose oral CBD (150-600 mg/d) may exert a therapeutic effect for social anxiety disorder, insomnia and epilepsy, but also that it may cause mental sedation. Potential pharmacokinetic and pharmacodynamic explanations for these results are discussed.”

12.) Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/

“Pretreatment of SAD patients with CBD significantly reduced anxiety, cognitive impairment, and discomfort in their speech performance (S) and significantly decreased alert in their anticipatory speech (A). The cognitive impairment, discomfort, and alert of SAD patients that received CBD had similar results to the HC during the SPST. These preliminary results indicate that a single dose of CBD can reduce the anxiety-enhancing effect provoked by SPST in SAD patients, indicating that this cannabinoid inhibits the fear of speaking in public, one of the main symptoms of the disorder.”